Objective: To observe the effect of Liancao-Xieli capsule on intestinal mucosal inflammatory factors and TLR4/PI3K/Akt/mTOR signaling pathway in mice with ulcerative colitis (UC); Methods: 40 male C57BL/6 mice were randomly divided into the control group, model group, Liancao-Xieli group and mesalazine group, with 10 mice in each group. In addition to the control group, the remaining three groups of mice were induced by 3％ dextran sulfate sodium (DSS) to induce acute UC model. During the modeling period, mice in each group were given corresponding drugs and normal saline by gavage. At the end of the experiment, HE staining was used to observe the pathological changes of colonic tissue in each group, and ELISA was used to detect the inflammatory factors (TNF-α, IL-6, IL-1β, IL-8, IL-17, and INF-γ) in serum and colonic tissue. The expression levels of TLR4/PI3K/Akt/mTOR signaling pathway related proteins were also detected by Western blot; Results: Compared with the model group, Liancao-Xieli capsule could significantly increase the colon length and decrease the score of colon histopathology in UC mice (P<0.01). In addition, the levels of TNF-α, IL-6, IL-1β, IL-8, IL-17, and INF-γ were significantly reduced in serum and colon tissue, and the expressions of TLR4, PI3K, p-Akt and p-mTOR were significantly down-regulated in Liancao-Xieyi group when compared with the model group (P0.05); Conclusion: Liancao-Xieli capsule can reduce the secretion of inflammatory factors, improve the intestinal mucosal damage and inflammatory response in UC by inhibiting the activation of TLR4/PI3K/Akt/mTOR signaling pathway.